# Parian Global Management

> Parian Global Management is a VC fund in New York backing Health Care and Biotechnology. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: New York, United States
- Total investments: 4
- Last investment: May 2021
- Lead investor: 25%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/parian-global-management-lp
- Website: https://parianglobal.com/

Parian Global Management is an investment firm that seeks to invest in dynamic industries.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 3 | 75% |
| Biotechnology | 3 | 75% |
| Medical Device | 3 | 75% |
| Medical | 2 | 50% |
| Life Science | 2 | 50% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series E | 2 | 50% |
| Series C | 1 | 25% |
| Series D | 1 | 25% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 75% |
| The Netherlands | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Binx Health | Binx Health is creating new categories of healthcare solutions that deliver on-demand testing to people where they need it most. With its proprietary, desktop, PCR-based point-of-care testing platforms and consumer mobile offerings, the company is redefining “convenient care” for the modern consumer | $104M | Series E | May 27, 2021 |  |
| Sera Prognostics | Sera is a women’s health diagnostics company dedicated to improving the lives of women and babies through precision pregnancy care. Sera provides pivotal information during pregnancy to physicians, designed to help improve the health of their patients, and to reduce the costs of healthcare delivery. Sera has a robust pipeline of innovativediagnostic tests focused on the prediction of preterm birth risk and other complications of pregnancy. Sera’s PreTRM® Test reports to a physician the individualized risk of spontaneous premature delivery in a pregnancy, enabling earlier proactive interventions in women with higher risk. | $100M | Series E | Apr 28, 2021 |  |
| Renovia | Renovia is a women-led developer of prescription digital therapeutics, dedicated to improving the lives of women with urinary incontinence and other pelvic floor disorders. The company's technology enables non-invasive, drug-free treatment via precise visualization of pelvic movement in real-time during pelvic floor muscle training, whilemonitoring usage and progress. It supplements its technology with adherence coaching from the Renovia Women’s Center as well as symptom and adherence reporting to prescribers. | $17M | Series C | Apr 19, 2021 |  |
| LUMICKS | LUMICKS delivers state-of-the-art technologies for the study of biology and cancer at the single-molecule and single-cell levels. It aims to build the unfinished bridge between structure and function at the molecular and cellular levels. Using its product C-Trap Optical Tweezers, Fluorescence Microscopy, scientists are able to analyze complexbiological processes in real-time. Similarly, the z-Movi Cell Avidity Analyzer enables the measurement and selection of immune cells based on their real-time interactions with target cells. | $93M | Series D | Apr 16, 2021 |  |

4 of 4 investments shown.

## Co-investors
- [Alta Life Sciences](https://shizune.co/investors/profile/alta-life-sciences) — VC Fund, 1 deal together
- [aMoon Fund](https://shizune.co/investors/profile/amoon) — VC Fund, 1 deal together
- [ArrowMark Partners](https://shizune.co/investors/profile/arrowpoint-partners) — VC Fund, 1 deal together
- [Ascension Ventures](https://shizune.co/investors/profile/ascension-ventures) — VC Fund, 1 deal together
- [Blue Ox Healthcare Partners](https://shizune.co/investors/profile/blue-ox-healthcare-partners) — VC Fund, 1 deal together
- [Elevance Health](https://shizune.co/investors/profile/elevance-health) — VC Fund, 1 deal together

## Similar investors

### Similar stage
- [Krungsri Finnovate](https://shizune.co/investors/profile/krungsri-finnovate) — VC Fund
- [Munich Venture Partners](https://shizune.co/investors/profile/munich-venture-partners) — VC Fund
- [yet2Ventures](https://shizune.co/investors/profile/yet2ventures) — VC Fund

## FAQ

### What does Parian Global Management invest in?

Parian Global Management invests primarily in Health Care, Biotechnology and Medical Device startups, most often at Series E and Series C stage. Most of the 4 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Parian Global Management last invest?

The most recent investment recorded for Parian Global Management closed in May 2021. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co